Avastin is a prescription-only medicine that is a solution for intravenous infusion.
In the trial, the women who received Avastin showed 52% reduction in the risk of their disease progressing as compared to women who received chemotherapy alone.
Additionally, the results from the trial also suggested tumor shrinkage (overall response rate) in 79% of women receiving the Avastin-based regimen compared to 57% of women who received chemotherapy alone.
Genentech Global Product Development chief medical officer and head Hal Barron said these data add to the growing body of evidence supporting Avastin’s potential role in this disease, which includes two previously presented Phase III clinical trials in women with newly diagnosed ovarian cancer.